Editas, BMS extend T cell deal; KalVista seeks partner for preclinical HAE program
Plus, news about Novo Holdings, Pepper Bio, G1 Therapeutics and Akari:
Editas, Bristol Myers Squibb add two years to T cell pact: The companies are …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
